Kandamurugu Manickam1,2, Monica R McClain3, Laurie A Demmer4, Sawona Biswas5, Hutton M Kearney6, Jennifer Malinowski7, Lauren J Massingham8,9, Danny Miller10, Timothy W Yu11,12, Fuki M Hisama13. 1. Division of Genetic and Genomic Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, USA. 2. The Ohio State University College of Medicine, Columbus, OH, USA. 3. Scientific and Strategic Affairs, Evidera | PPD, Waltham, MA, USA. 4. Division of Medical Genetics, Department of Pediatrics, Atrium Health's Levine Children's Hospital, Charlotte, NC, USA. 5. Division of Adult Genetics, Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 6. Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. 7. Write Inscite, LLC, South Salem, NY, USA. 8. Division of Medical Genetics, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI, USA. 9. Alpert School of Medicine at Brown University, Providence, RI, USA. 10. MEPAN Foundation, Corte Madera, CA, USA. 11. Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA. 12. Harvard Medical School, Boston, MA, USA. 13. Division of Medical Genetics, Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
Abstract
PURPOSE: To develop an evidence-based clinical practice guideline for the use of exome and genome sequencing (ES/GS) in the care of pediatric patients with one or more congenital anomalies (CA) with onset prior to age 1 year or developmental delay (DD) or intellectual disability (ID) with onset prior to age 18 years. METHODS: The Pediatric Exome/Genome Sequencing Evidence-Based Guideline Work Group (n = 10) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence to decision (EtD) framework based on the recent American College of Medical Genetics and Genomics (ACMG) systematic review, and an Ontario Health Technology Assessment to develop and present evidence summaries and health-care recommendations. The document underwent extensive internal and external peer review, and public comment, before approval by the ACMG Board of Directors. RESULTS: The literature supports the clinical utility and desirable effects of ES/GS on active and long-term clinical management of patients with CA/DD/ID, and on family-focused and reproductive outcomes with relatively few harms. Compared with standard genetic testing, ES/GS has a higher diagnostic yield and may be more cost-effective when ordered early in the diagnostic evaluation. CONCLUSION: We strongly recommend that ES/GS be considered as a first- or second-tier test for patients with CA/DD/ID.
PURPOSE: To develop an evidence-based clinical practice guideline for the use of exome and genome sequencing (ES/GS) in the care of pediatric patients with one or more congenital anomalies (CA) with onset prior to age 1 year or developmental delay (DD) or intellectual disability (ID) with onset prior to age 18 years. METHODS: The Pediatric Exome/Genome Sequencing Evidence-Based Guideline Work Group (n = 10) used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) evidence to decision (EtD) framework based on the recent American College of Medical Genetics and Genomics (ACMG) systematic review, and an Ontario Health Technology Assessment to develop and present evidence summaries and health-care recommendations. The document underwent extensive internal and external peer review, and public comment, before approval by the ACMG Board of Directors. RESULTS: The literature supports the clinical utility and desirable effects of ES/GS on active and long-term clinical management of patients with CA/DD/ID, and on family-focused and reproductive outcomes with relatively few harms. Compared with standard genetic testing, ES/GS has a higher diagnostic yield and may be more cost-effective when ordered early in the diagnostic evaluation. CONCLUSION: We strongly recommend that ES/GS be considered as a first- or second-tier test for patients with CA/DD/ID.
Authors: Piero Perucca; Ingrid E Scheffer; A Simon Harvey; Paul A James; Sebastian Lunke; Natalie Thorne; Clara Gaff; Brigid M Regan; John A Damiano; Michael S Hildebrand; Samuel F Berkovic; Terence J O'Brien; Patrick Kwan Journal: Epilepsy Res Date: 2017-02-07 Impact factor: 3.045
Authors: Holger J Schünemann; Reem Mustafa; Jan Brozek; Nancy Santesso; Pablo Alonso-Coello; Gordon Guyatt; Rob Scholten; Miranda Langendam; Mariska M Leeflang; Elie A Akl; Jasvinder A Singh; Joerg Meerpohl; Monica Hultcrantz; Patrick Bossuyt; Andrew D Oxman Journal: J Clin Epidemiol Date: 2016-02-27 Impact factor: 6.437
Authors: Ali H Mokdad; Mohammad Hossein Forouzanfar; Farah Daoud; Arwa A Mokdad; Charbel El Bcheraoui; Maziar Moradi-Lakeh; Hmwe Hmwe Kyu; Ryan M Barber; Joseph Wagner; Kelly Cercy; Hannah Kravitz; Megan Coggeshall; Adrienne Chew; Kevin F O'Rourke; Caitlyn Steiner; Marwa Tuffaha; Raghid Charara; Essam Abdullah Al-Ghamdi; Yaser Adi; Rima A Afifi; Hanan Alahmadi; Fadia AlBuhairan; Nicholas Allen; Mohammad AlMazroa; Abdulwahab A Al-Nehmi; Zulfa AlRayess; Monika Arora; Peter Azzopardi; Carmen Barroso; Mohammed Basulaiman; Zulfiqar A Bhutta; Chris Bonell; Cecilia Breinbauer; Louisa Degenhardt; Donna Denno; Jing Fang; Adesegun Fatusi; Andrea B Feigl; Ritsuko Kakuma; Nadim Karam; Elissa Kennedy; Tawfik A M Khoja; Fadi Maalouf; Carla Makhlouf Obermeyer; Amitabh Mattoo; Terry McGovern; Ziad A Memish; George A Mensah; Vikram Patel; Suzanne Petroni; Nicola Reavley; Diego Rios Zertuche; Mohammad Saeedi; John Santelli; Susan M Sawyer; Fred Ssewamala; Kikelomo Taiwo; Muhammad Tantawy; Russell M Viner; Jane Waldfogel; Maria Paola Zuñiga; Mohsen Naghavi; Haidong Wang; Theo Vos; Alan D Lopez; Abdullah A Al Rabeeah; George C Patton; Christopher J L Murray Journal: Lancet Date: 2016-05-09 Impact factor: 79.321
Authors: J Delanne; S Nambot; A Chassagne; O Putois; A Pelissier; C Peyron; E Gautier; J Thevenon; E Cretin; A L Bruel; V Goussot; F Ghiringhelli; R Boidot; F Tran Mau-Them; C Philippe; A Vitobello; L Demougeot; C Vernin; A S Lapointe; M Bardou; M Luu; C Binquet; C Lejeune; L Joly; C Juif; A Baurand; C Sawka; G Bertolone; Y Duffourd; D Sanlaville; P Pujol; D Geneviève; F Houdayer; C Thauvin-Robinet; L Faivre Journal: Eur J Med Genet Date: 2018-08-28 Impact factor: 2.708
Authors: S L Sawyer; T Hartley; D A Dyment; C L Beaulieu; J Schwartzentruber; A Smith; H M Bedford; G Bernard; F P Bernier; B Brais; D E Bulman; J Warman Chardon; D Chitayat; J Deladoëy; B A Fernandez; P Frosk; M T Geraghty; B Gerull; W Gibson; R M Gow; G E Graham; J S Green; E Heon; G Horvath; A M Innes; N Jabado; R H Kim; R K Koenekoop; A Khan; O J Lehmann; R Mendoza-Londono; J L Michaud; S M Nikkel; L S Penney; C Polychronakos; J Richer; G A Rouleau; M E Samuels; V M Siu; O Suchowersky; M A Tarnopolsky; G Yoon; F R Zahir; J Majewski; K M Boycott Journal: Clin Genet Date: 2015-09-22 Impact factor: 4.438
Authors: Lauge Farnaes; Amber Hildreth; Nathaly M Sweeney; Michelle M Clark; Shimul Chowdhury; Shareef Nahas; Julie A Cakici; Wendy Benson; Robert H Kaplan; Richard Kronick; Matthew N Bainbridge; Jennifer Friedman; Jeffrey J Gold; Yan Ding; Narayanan Veeraraghavan; David Dimmock; Stephen F Kingsmore Journal: NPJ Genom Med Date: 2018-04-04 Impact factor: 8.617
Authors: Jennifer Malinowski; David T Miller; Scott E Hickey; Jun Shen; Laurie Demmer; Jennifer Gannon; Elaine Maria Pereira; Molly C Schroeder; Maren T Scheuner; Anne Chun-Hui Tsai Journal: Genet Med Date: 2020-03-23 Impact factor: 8.822
Authors: Beverly L Davidson; Guangping Gao; Elizabeth Berry-Kravis; Allison M Bradbury; Carsten Bönnemann; Joseph D Buxbaum; Gavin R Corcoran; Steven J Gray; Heather Gray-Edwards; Robin J Kleiman; Adam J Shaywitz; Dan Wang; Huda Y Zoghbi; Terence R Flotte; Sitra Tauscher-Wisniewski; Cynthia J Tifft; Mustafa Sahin Journal: Mol Ther Date: 2022-05-17 Impact factor: 12.910
Authors: Amelle Shillington; Martine Lamy; Kelli C Dominick; Michael Sorter; Craig A Erickson; Robert Hopkin Journal: Front Genet Date: 2022-06-13 Impact factor: 4.772
Authors: Brenda Finucane; Matthew T Oetjens; Alicia Johns; Scott M Myers; Ciaran Fisher; Lukas Habegger; Evan K Maxwell; Jeffrey G Reid; David H Ledbetter; H Lester Kirchner; Christa Lese Martin Journal: Genet Med Date: 2021-11-18 Impact factor: 8.864
Authors: Chaofan Zhang; Angad Jolly; Brian J Shayota; Juliana F Mazzeu; Haowei Du; Moez Dawood; Patricia Celestino Soper; Ariadne Ramalho de Lima; Bárbara Merfort Ferreira; Zeynep Coban-Akdemir; Janson White; Deborah Shears; Fraser Robert Thomson; Sarah Louise Douglas; Andrew Wainwright; Kathryn Bailey; Paul Wordsworth; Mike Oldridge; Tracy Lester; Alistair D Calder; Katja Dumic; Siddharth Banka; Dian Donnai; Shalini N Jhangiani; Lorraine Potocki; Wendy K Chung; Sara Mora; Hope Northrup; Myla Ashfaq; Jill A Rosenfeld; Kati Mason; Lynda C Pollack; Allyn McConkie-Rosell; Wei Kelly; Marie McDonald; Natalie S Hauser; Peter Leahy; Cynthia M Powell; Raquel Boy; Rachel Sayuri Honjo; Fernando Kok; Lucia R Martelli; Vicente Odone Filho; Donna M Muzny; Richard A Gibbs; Jennifer E Posey; Pengfei Liu; James R Lupski; V Reid Sutton; Claudia M B Carvalho Journal: HGG Adv Date: 2021-12-03